$411M
The Series A round was co-led by Forbion and General Atlantic to support clinical trials and portfolio expansion.
VB
Verdiva Bio
Verdiva Bio develops next-generation oral therapies and combination treatments for obesity.
London, UK
$411MTotal raised
Verdiva Bio is a biotechnology company based in London that develops advanced treatments for obesity and cardiometabolic disorders.
Categories
Founders
KF
Khurem Farooq
Founder
Khurem is the chief executive officer and co-founder of Verdiva Bio. He previously served as chief executive officer at Aiolos Bio and Gyroscope Therapeutics, alongside leadership roles at Genentech and sanofi-aventis.
LinkedIn